These results reinforce the emerging concept of TIM-3 and Gal-9 as interconnected immune checkpoints that not only blunt antitumor immunity but also contribute to the spatial and functional organization of immune infiltrates within the tumor microenvironment, highlighting their potential as therapeutic targets in immune checkpoint blockade strategies. The gene discussed is LGALS9; the disease is neoplasm.